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Abstract
Background: Mannose-binding lectin (MBL) is a key component of innate immunity. Low serum MBL levels, related
to promoter polymorphism and structural variants, have been associated with an increased risk of infection. The aim of
this work was to analyse the incidence and severity of infections and mortality in relation to the MBL2 genotype and
MBL levels in patients underwent allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
Results: This was a prospective cohort study of 72 consecutive patients underwent Allo-HSCT between January 2007
and June 2009 in a tertiary referral centre. Three periods were considered in the patients’ follow-up: the early period
(0–30 days after Allo-HSCT), the intermediate period (30–100 days after Allo-HSCT) and the late period (> 100 days after
Allo-HSCT). A commercial line probe assay for MBL2 genotyping and an ELISA Kit were used to measure MBL levels. A
total of 220 episodes of infection were collected in the 72 patients. No association between donor or recipient MBL2
genotype and infection was found. The first episode of infection presented earlier in patients with pre-transplant MBL
levels of < 1000 ng/ml (median 6d vs 8d, p = 0.036). MBL levels < 1000 ng/ml in the pre-transplant period (risk ratio (RR)
2.48, 95% CI 1.00–6.13), neutropenic period (0–30 days, RR 3.28, 95% CI 1.53–7.06) and intermediate period (30–100
days, RR 2.37, 95% CI 1.15–4.90) were associated with increased risk of virus infection. No association with bacterial or
fungal disease was found. Mortality was associated with pre-transplant MBL levels < 1000 ng/ml (hazard ratio 5.55, 95%
CI 1.17–26.30, p = 0.03) but not with MBL2 genotype.
Conclusions: Patients who underwent Allo-HSCT with low pre-transplant MBL levels presented the first episode of
infection earlier and had an increased risk of viral infections and mortality in the first 6 months post-transplant. Thus,
pre-transplant MBL levels would be important in predicting susceptibility to viral infections and mortality and might be
considered a biomarker to be included in the pre-transplantation risk assessment.
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Background
Despite the improvement in diagnosis and therapy, inva-
sive bacterial, virus and fungal infections are still some of
the most important barriers to the success of allogeneic
haematopoietic stem cell transplantation (Allo-HSCT) [1–
3]. Mannose-binding lectin (MBL), a key component of
innate immunity response, is a C-type serum lectin that
binds microbial surface carbohydrates and mediates
opsono-phagocytosis both directly and by activation of the
lectin complement pathway [4, 5]. Mutations in the struc-
tural and regulatory sequence of the MBL2 gene lead to
inter-individual variations in serum MBL levels which
have been associated with increased risk of infections [5–
7]. Low serum MBL levels, related to promoter poly-
morphism and structural variants, have been associated
with an increased risk of infection [7].
In patients with haematological malignancies receiving
chemotherapy, increased susceptibility to infection and
prolonged duration of febrile neutropenic episodes have
been associated with MBL deficiency [8–10]. However,
these observations were not consistent in all study co-
horts [11–13]. In autologous HSCT [14–17] showed
conflicting results regarding the influence of MBL2
genotype and functional MBL deficiency on infection
risk. In myeloablative, total body irradiation (TBI) -con-
ditioned transplantation-, MBL2 variants have been
associated with an increased risk of infection [18]. None-
theless, other studies involving Allo-HSCT showed
contradictory results regarding the influence of MBL2
polymorphisms and MBL deficiency on infection risk
[18–25]. In addition, it is difficult to compare these dif-
ferent studies, because of some studies focused on MBL
levels while others determined MBL2 genotype, and even
more because of different MBL cut-off levels and differ-
ent MBL2 genotype or haplotype combinations that are
considered deficient [14–25]. Furthermore, over the
years, research on MBL in Allo-HSCT has addressed the
question of whether or not MBL is associated with their
prognosis without reaching clear conclusions [13].
The aim of our study was to investigate the incidence,
severity of infections, and mortality according to MBL2
genotype and MBL levels in a prospective cohort of
myeloablative and non-myeloablative Allo-HSCT pa-
tients carrying out a follow up from the pre-transplant
conditioning to 6 months after the transplantation.
Results
Infections
From February 28th, 2007 to June 30th, 2009, 77 con-
secutive Allo-HSCT patients were included in the study.
Five patients were excluded for not following the sam-
pling protocol. The main demographic data are shown
in Table 1 and supplementary Table 1.
A total of 220 episodes of infection were collected, and
150 of them microbiologically documented (68.2%).
There were 4 (6.6%) patients who had no infections
during the follow up. Seventy-eight infections occurred
in the early period, 52 in the intermediate period and 20
in the late period (Table 2). The average number of
episodes per patient was 3 (SD = 2.1), with a minimum
of 1 and a maximum of 9. The number of infections
according to the conditioning regimen was 82.4% in
myeloablative and 76.3% in non-myeloablative (p = 0.36).
However, infections started later in patients with non-
myeloablative allo-HSCT (median of 6 days in myeloabla-
tive conditioning regimen versus 9 days non-myeloablative,
p = 0.018), with a significant HR = 1.76 (95% CI 1.06–2.71).
Donors and recipients MBL2 genotypes and infection
MBL2 genotypes were analysed in 61 (84.7%) recipients
and 38 (52.8%) donors. Recipients and donors were
Table 1 Characteristics of 72 patients with Allo-HSCT
Patients
Age (median years, range) 44 (13–63)
Sex (male) 35 (48.6%)
Haematologic disease
Acute Myeloblastic Leukaemia 18 (25.0%)
Acute Lymphoblastic Leukaemia 13 (18.1%)
Myelodysplastic syndrome 8 (11.1%)
Myeloproliferative syndrome 8 (11.1%)
Hodgkin Lymphoma 6 (8.3%)
Multiple Myeloma 5 (6.9%)
Chronic Lymphoproliferative Disorder 7 (9.7%)
NHLa 3 (4.2%)
Bone Marrow Aplasia 3 (4.2%)





Busulfan + Cyclophosphamide + /−ATG 23 (32.0%)
Fludarabine + Melphalan + /−ATG 18 (25.0%)
Radiotherapy + Cyclophosphamide + /−ATG 12 (16.7%)
Busulfan + fludarabine 11 (15.3%)
Others 8 (11.1%)
MBL levels (ng/mL) (median, IQRb)
Pre-transplant 1135 (2918–466)
Early period 1997.5 (4056–464)
Intermediate period 1665 (3765–337.3)
Late period 1264 (3219.5–468.4)
aNHL: Non-Hodgkin’s Lymphoma
bIQR: interquartile range (75th–25th percentiles)
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divided into two groups, each according to their MBL2
genotype: 1) homozygous donors (AA) for wild type
MBL2 genotype (n = 24) and AO/OO donors (n = 14),
which included heterozygous donors (AO) (n = 13) and
homozygous mutant donors (OO) (n = 1); and 2) recipi-
ents homozygous (AA) for wild type MBL2 genotype
(n = 34) and AO/OO recipients (n = 27), which included
heterozygous recipients (AO) (n = 23), and homozygous
mutant recipients (OO) (n = 4) (supplementary Table 2).
We did not find a significant increase of microbiologic-
ally documented Gram-positive (RR 1.71; CI 95% 0.90–
3.28), Gram-negative (RR 1.56 CI 95% 0.90–2.69), virus
(RR 1.50 CI 95% 0.69–3.24) or fungal infections (RR 1.00
CI 95% 0.03–2.66) in patients whose donors had low-
producer MBL2 genotypes (AO and OO genotypes).
These findings did not differ when we tested different
combinations of patient /donor MBL2 genotypes.
Recipients with low-producer MBL2 genotypes (AO
and OO genotypes) had a tendency to have more epi-
sodes of infection (2.42, SD = 1.84) than those with
MBL2 wild-type genotype (AA genotypes) (1.74, SD =
1.04), p = 0.05. However, no association between MLB2
polymorphisms and the risk of Gram-positive (RR 1.02,
95% CI 0.60–1.74), Gram-negative infections (RR 0.89,
95% CI 0.52–1.52), viruses (RR 0.63, 95% CI 0.30–1.34)
or fungal infections (RR 0.31, 95% CI 0.03–2.66) was
found during the first 6 months after the transplant.
Supplementary Table 3 shows patients with MBL2
genotypes and risk of infections.
Serum MBL levels and infection
Patients with MBL levels < 1000 ng/ml in the pre-
transplant period presented the first post-transplant
infection episode earlier (median 6d vs. 8d, p = 0.036,
HR adjusted by conditioning regimen 1.72, 95% CI
0.91–3.25) (Fig. 1). Additionally, a significant association
was found between MBL levels < 1000 ng/mL in the pre-
transplant (before conditioning) and the risk of virus
infection after Allo-HSCT, in the early (RR 2.48, 95% CI
1.00–6.13), neutropenic (RR 3.28, 95% CI 1.53–7.06) and
intermediate periods (RR 2.37, 95% CI 1.15–4.90). How-
ever, this finding was not observed in the late period.
Among the virus infections, cytomegalovirus (CMV) was
the most frequent infection (Table 2), and patients with
low serum MBL levels had more episodes of CMV dis-
ease than those with normal levels, although these differ-
ences were not statistically significant. In the same way,
no significant differences were observed between MBL
levels and bacterial or fungal infections. The adjusted
ORs are shown in Fig. 2 (2a, 2b, 2c, 2d).
Effect of MBL levels and infections on survival
Sixteen (22.2%) patients died (7 with myeloablative con-
ditioning and 9 non-myeloablative). Causes of death in
12 patients with MBL levels < 1000 ng/mL , were: 6
patients died due to an infection (2 pulmonary aspergil-
losis, 2 Pseudomonas aeruginosa bacteremia, 1 Klebsi-
ella pneumoniae bacteremia and 1 Pneumocystis jiroveci
pneumonia), 2 patients because of graft versus host dis-
ease (GVHD), 2 patients due to a progression of the dis-
ease and 1 patient died due to a hemorrhage. Of the 4
patients who died and had MBL levels> 1000 ng/mL, 3
died due to an infection (1 pulmonary aspergillosis, 1
Pseudomonas aeruginosa bacteremia and another one E.
coli and Nocardia spp. bacteremia) and 1 due to a multi-
organ failure of unknown cause. Aspergillus and viral in-
fections were associated with mortality (Figs. 3 and 4). It
was estimated that patients who developed Aspergillus
infection had a 3.56-fold higher death hazard than pa-
tients who did not (95% CI 0.99–12.70, p = 0.05). Mean
survival time over the 6-month follow-up period in pa-
tients with and without Aspergillus infection was 139.60
days (95% CI 109.95–169.25) and 161.16 days (95% CI
150.40–171.92 respectively, p = 0.036) (Fig. 3a). Similarly,
patients with a virus infection had a 2.73-fold higher
death hazard than patients who did not (95% CI 0.99–
7.55, p = 0.052). Mean survival time over the 6-month
follow-up period in patients with and without virus
infection was 146.43 days (95% CI 124.90–167.96)
and 165.87 days (95% CI 155.03–176.72 respectively,
p = 0.043) (Fig. 3b).
MBL2 genotypes were available in 12 out of the 16
patients who died (3 YA/YA, 3 XA/YA, 4 YA/O, 1 XA/
O and 1 O/O). There was no relationship between the
Table 2 Microbiologically documented episodes of infection
Microorganisms Periods
Neutropenica Intermediateb Latec Total d
N (%) N (%) N (%) N (%)
Bacteria 63 (80.8) 27 (51.9) 11 (55.0) 101 (67.3)
Gram-positive 39 (50.0) 8 (15.4) 3 (15.0) 50 (33.3)
Gram-negative 20 (25.6) 14 (26.9) 7 (35.0) 41 (27.3)
Polymicrobial 4 (5.1) 5 (9.6) 1 (5.0) 10 (6.7)
Virus 13 (16.7) 22 (42.3) 4 (20.0) 39 (26.0)
CMVe 5 (6.4) 18 (34.6) 4 (20.0) 27 (18.0)
Others non CMVf 8 (10.3) 4 (7.7) 12 (8.0)
Fungi 2 (2.6) 2 (3.8) 4 (20.0) 8 (5.3)
Candida 2 (2.6) 1 (5.0) 3 (2.0)
Aspergillus 2 (3.8) 3 (15.0) 5 (3.3)
P. jirovecii 1 (5.0) 1 (0.7)
Protozoa 1 (1.9) 1 (0.7)
Total 78 52 20 150
a0–30 days after Allo-HSCT; b30–100 days after Allo-HSCT; c > 100 days
after Allo-HSCT
dTotal episodes of infection; eCMV: Cytomegalovirus; fOthers non CMV virus:
neutropenic period (3 herpesvirus, 2 polyomavirus, 1 herpes simplex virus type
1, 1 respiratory syncytial virus and 1 rotavirus), intermediate period (2 herpes
simplex virus type 1, 1 adenovirus and 1 polyomavirus)
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Fig. 1 Timing of the first post-transplant episode of infection in patients according to pre-Allo-HSCT MBL levels
Fig. 2 MBL levels < 1000 ng/mL and adjusted risk of bacterial, virus and fungal infections in 72 patients with Allo-HSCT. Figure 2a, MBL levels pre-
transplant (before conditioning); Fig. 2b, neutropenic period (0–30 d); Fig. 2c, intermediate period (30-100d) and Fig. 2d, late period (100–180 d)
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recipient’s low producer MBL2 genotypes and mortality
(RR 1.26, 95% CI 0.46–3.47, p = 0.44). However, recipi-
ents with pre-transplant MBL levels < 1000 ng/mL had a
significantly higher mortality rate than those with levels
> 1000 ng/mL (HR 5.55, 95% CI 1.17–26.30, p = 0.03). In
addition, the mean survival time of patients with pre-
transplant MBL levels < 1000 ng/mL was significantly
lower (143.95 days; 95% CI 121.49–166.41) than those
with levels > 1000 ng/mL (169.15 days; 95% CI 154.57–
183.66, p = 0.015). A Kaplan–Meier plot of survival by
MBL status is shown in Fig. 4.
Discussion
This prospective study focused on analysing the influ-
ence of MBL2 polymorphisms and MBL serum levels in
the incidence of infections and outcome of myeloablative
and non-myeloablative Allo-HSCT patients. Patients
were followed from the conditioning until 180 days after
transplant. To date, the studies describing the incidence
of infections in Allo-HSCT related to MBL2 gene
variants and MBL levels have shown conflicting results.
The results of our study indicate that donor and/or
recipient MBL2 genotype was not associated with an
increased number of infections by Gram-positive, Gram-
negative, virus or fungal infections in the six months
following transplantation. These findings contrast with
those of Mullighan et al. [22] and Granell et al. [20],
which showed that the MBL2 genotype of both recipi-
ents and donors influenced the risk of bacterial and
invasive fungal infections, respectively, after Allo-HSCT.
Fig. 3 Survival time according to presence of Aspergillus and viral infections over the 6 months follow-up. Figure 3a, Aspergillus infection; 3b,
virus infections
Fig. 4 Survival time by pre-Allo-HSCT MBL status over the 6 months follow-up
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However, our results did support those found by Neth
et al. [23], which suggested that donors’ MBL2 genotype
did not influence infection rates, and the results of
Rocha et al. [21], who examined 107 HLA identical
sibling Allo-HSCT recipients with myeloablative condi-
tioning and found no association between MBL2 gene
polymorphisms and the development of bacterial, viral
or fungal infections during the first 180 days after trans-
plant. Currently, there are conflicting data about
whether MBL deficiency is a good predictor of increased
risk of infection. In our study, patients with pre-
transplant MBL levels < 1000 ng/mL presented the first
episode of infection earlier on. Similar results have been
published about neutropenic post-chemotherapy pa-
tients, in whom low MBL levels have also been described
to be associated with earlier infections [9, 25]. In
addition, patients with MBL levels < 1000 ng/mL in the
pre-transplant and during the first 100 days after the
transplant, had a significantly increased risk (2 to 8 times
higher) of viral infection, mainly for CMV infection,
although in this case the difference did not reach statis-
tical significance. Our results are consistent with previ-
ously reported data regarding the association of viral
infection and MBL deficiency [26–28]. MBL binds to
influenza A virus, and therefore, it would inhibit haem-
agglutinin activity and infectivity [29]. Furthermore,
MBL deficiency has also been related with herpes sim-
plex virus (HSV)-2 infection and with CMV infection
and reactivation in kidney and lung transplant recipients
[28–30]. Nevertheless, different results have reported the
association of MBL deficiency with viral infections in
Allo-HSCT recipients [18, 19, 23]. Chaudhry et al. [19]
did not find an association between MBL levels < 400
ng/mL and viral infections in 110 paediatric Allo-HSCT
recipients. However, Neth et al. [23] found an associ-
ation between MBL levels < 400 ng/mL and HSV/vari-
cella zoster virus (VZV) reactivation in 131 Allo-HSCT
recipients, and Osthoff et al. [18] showed an independ-
ent association between MBL levels < 1000 ng/mL and
the occurrence of severe herpes virus infections in 44
Allo-HSCT recipients. These findings would suggest an
important role of the innate immunity in the control of
an important viral complication after Allo-HSCT
transplantation.
Likewise, there are conflicting results or contradictory
data about whether MBL2 genotypes or MBL deficiency
could be used as mortality predictors in HSCT patients
[13, 16, 17, 30, 31]. In the present study, the cause of
death in all patients was infection, predominantly viral
and Aspergillus infection. Recent report shows associ-
ation of fungal invasive disease with death in patients
with haematologic malignancy [13]. We did not find a
relation between the recipient or donor MBL2 genotype
and mortality. Our findings are in agreement with those
of Mulligan et al. [17], who did not find a relationship
between mortality and MBL2 genotype, and disagree
with our previous results in autologous HSCT [16] or
those reported by other groups with immunosuppressed
patients who had low-producing MBL2 genotypes [30,
31]. On the other hand, we found that MBL levels <
1000 ng/mL could be a biomarker predictor of death
since mortality was associated with low pre-transplant
MBL levels. Similar findings have been published in pa-
tients with solid organ transplant, pneumonia or
pneumococcal sepsis [32–34]. Low recipient serum MBL
levels were associated with increased inflammation and
apoptosis, [32] and have been described as an independ-
ent risk factor for poor prognosis in patients with pneu-
monia [35] and were associated with an increased
severity of pneumococcal sepsis [34]. A meta-analysis
published by Goa et al. in patients with sepsis showed a
correlation between decreased MBL levels and develop-
ment of sepsis, which the authors attributed to a
possible interaction between coagulation patterns, pro-
inflammatory cytokines and the complement system
[35]. To date, there is a shortage of reports regarding the
effects of MBL levels on the clinical outcome of Allo-
HSCT patients. A recent retrospective study by Riwes
et al. [13] reported no association between low MBL
levels and an increased risk of invasive fungal disease or
overall survival in patients with haematologic malignancy.
This study presents some limitations. First that it is a
single-centre study, with potential for uncontrolled se-
lection biases and with small simple size. Nevertheless, is
a prospective study without variation in the methodolo-
gies, something that does not occur when drawing
patients from multiple centres. To avoid information
bias, this was collected prospectively; the sample analysis
was blinded for the presence or absence of infection and
the measurement of the effect (presence of infection);
the infectious disease physicians using the same diagnos-
tic criteria (according to the IDSA criteria) carried out
the analysis; and physicians responsible for the monitor-
ing and diagnosis of infections were masked with respect
to the presence of genetic polymorphisms and/or MBL
levels. Second, this study finished time ago and the viral
o fungal prophylaxis of infection could have been
changed and could influence our results. However, the
procedure of HSCT is totally similar to the performed in
a Hematology Service at present and to our knowledge,
there are no extensive studies in the last years regarding
the role of MBL in Allo-HSCT; in addition, our study
has an important value because of a prospective cohort
that included patients with myeloablative and non-
myeloablative conditioning (the majority of studies on
MBL and polymorphisms in patients with Allo-HSCT
studied only those patients with myeloablative condi-
tioning), this allows us to study a more heterogeneous
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population that is closer to the reality of the patients
admitted to the Hematology Service. On the other hand,
previous retrospective published studies on the role of
innate immunity to infection or mortality in HSCT
patients included old cohorts [14, 23], when probably
viral and aspergillus prophylaxis were different to ours,
with similar findings.
Conclusions
In summary, our results would suggest that low pre-
transplant MBL levels, but not MBL2 genotype, could
predispose patients undergoing Allo-HSCT to have the
first episode of infection earlier and to increase the risk
of viral infection. This would support the hypothesis that
phenotype might be more important than genotype in
predicting susceptibility to viral infections since this
association would be related with MBL levels. Moreover,
low pre-transplant MBL levels and no MBL2 genotype
would predict mortality in Allo-HSCT patients. Consid-
ering our findings, we could think that determination of
the pre-Allo-HSCT MBL serostatus should be consid-
ered a useful biomarker for viral infection and mortality
and should be included in the pre-transplantation risk
assessment. However, given the contradictory findings
that exist regarding the MBL studies after Allo-HSCT
a larger study is required to replicate or refute our
findings.
Methods
A prospective cohort study of all patients who received
an Allo-HSCT was carried out between February 2007
and June 2009 at a tertiary care university hospital
(1000-bed). All Allo-HSCT patients were > 13 years old,
and none of them presented any primary or secondary
immunodeficiencies (solid neoplasms, HIV infection,
autoimmune diseases). Patients were followed for a
period of six months, after inclusion in the study.
Endpoint definition
Intercurrent infections were prospectively collected from
the first day after infusion (day+ 1) and for the next 180
days after transplantation. We considered 3 periods: the
early period (0–30 days after Allo-HSCT), the interme-
diate period (30–100 days after Allo-HSCT) and the late
period (> 100 days after Allo-HSCT). Infections were
recorded by the clinical research associates from the
institution using a standardized data collection form,
following the protocols of the Hematology Department
for autologous stem cell transplantation (ASCT) and Allo-
SCT [17], in agreement with the clinical guidelines of the
Infectious Diseases Society of America (IDSA) [36].
Prophylactic measures included isolation in high-pressure
rooms with air filters, the administration of intravenous
acyclovir at prophylactic doses from day 3, anti-bacterial
prophylaxis with cotrimoxazole from day 30 after trans-
plant and antifungal prophylaxis with fluconazole or
caspofungin.
As previously described [17], we followed the protocols
of the Hematology Department for definitions of an infec-
tious episode (microbiologically or a clinically documented
infection), major infection (either confirmed sepsis or
systemic inflammatory response syndrome with highly
suggestive radiographic or clinical features who received
specific antibiotherapy); severe herpes virus infection
(as an invasive viral infection requiring treatment and
hospitalization); clinically significant CMV infection/reacti-
vation (positive CMV blood culture or CMV-pp65 antige-
nemia assay or polymerase chain reaction (PCR) for CMV
DNA (> 400 copies/mL, COBAS Amplicor CMV Monitor,
Roche Diagnostics) and symptoms of organ dysfunction
were required to fulfil the criteria of a clinically signifi-
cant CMV infection/reactivation [37]). Episodes of
asymptomatic CMV reactivation, local HSV reactiva-
tion, primary VZV, dermatological varicella zoster re-
activation, patients with a single positive blood culture
with contaminant skin bacteria, upper respiratory tract
infections and culture-negative interstitial pneumonitis
were excluded.
MBL2 genotyping
Blood samples from transplant patients was collected
the day before the start of conditioning. In the case of
donors, it was collected on the day of infusion in related
donors. Eighteen unrelated donors were excluded for
this analysis. There were 16 related donors in whom the
sample could not be obtained; therefore, the determin-
ation of the genotype in the donors was finally per-
formed in 34 patients. As previously described [17],
genomic DNA from patients and controls was purified
from blood samples by using the Maxwell 16 Genomic
DNA Purification system (Promega Biotech Ibérica S.L.,
Madrid, Spain) and for MBL2 gene amplification and
genotyping, the INNO-LiPA MBL2 (Innogenetics Diag-
nostica Iberia S.L.U, Barcelona, Spain) was used, follow-
ing the manufacturer’s instructions. We analysed the 6
variations in the human MBL2 gene (−550G > C,
−221G > C, +4C > T, R52C, G54D, and G57E), the seven
common haplotypes and the 28 possible resulting diplo-
types. Exonic structural variants (A: normal allele, and B,
C and D: mutant alleles, which together were designated
allele O) and promoter polymorphisms (H/L, Y/X and
P/Q) were analysed. Variants YA/YA, XA/XA and YA/XA
were classified as A/A. Those with any mutation in the
exon such as YA/O and XA/O were classified as A/O, and
homozygous individuals with structural variants in the
exon were considered O/O. Thus, patients were divided
into two groups according to their MBL2 genotype: 1)
normal homozygous patients (AA), and 2) patients with
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AO and OO genotypes, who as described earlier, were
considered to be lower MBL producers [15].
MBL serum levels measurement
Serum samples were used for the determination of MBL
levels. These samples were obtained from patients before
conditioning, weekly during the first month after the
transplant and monthly during the following 5 months
after the transplant. If an episode of infection occurred,
biweekly serum was collected until the resolution of the
episode.
Serum samples were collected and stored at − 80 °C until
analysis. Quantification of functional MBL was performed
by an investigator blinded to any recipient data using a
commercially available ELISA Kit (MBL Oligomer ELISA
Kit, Bio Porto Diagnostics A/S, Copenhagen, Denmark)
following manufacturer recommendations. Functional
MBL deficiency was defined as serum levels below
1000 ng/mL [18].
Statistical analysis
As previously described [17], statistical analysis was per-
formed, as required, using χ2 and Fisher’s exact test when
necessary, as well as Student’s t test, or the Mann-Whitney
test. A two-tailed p < 0.05 was considered statistically
significant. To analyse the association betweenMBL2 geno-
type and MBL levels, relative risks (RR) and adjusted odds
ratios (OR) and their 95% confidence intervals (CI) were
calculated; the risk of concomitant infections was the
dependent variable (overall and by microorganisms). The
effect of MBL levels pre-transplant (before the start of con-
ditioning) and after transplantation (early, intermediate and
late periods) on the risk of infection, was analysed. Multi-
variate analysis was performed using logistic regression: a
regression model was constructed for each type of infec-
tion, with infection-related variable being the outcome and
the independent variable being the MBL2 genotypes and
MBL levels, adjusted for sex, age, conditioning regimen,
acute or chronic GVHD, and number of treatment lines.
We used Kaplan-Meyer survival analysis with the log-rank
test for comparisons between survival time and time to
event or time until a certain event (1st infection). To esti-
mate survival rate over time a Cox regression was applied
as a function of several covariates. Hazard ratios (HR) and
their 95% CI were calculated. Data were analysed using
Stata (SE 10.0, Stata Corporation, College Station, TX) and
SPSS (v19) (SPSS Inc., Chicago, IL) statistical software.
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